Marina Vengalil
Internal Medicine · Garland, TXNPI 1396770947
Payments from drug & device makers
Across 219 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$635
- Amgen$516
- AstraZeneca$390
- Pfizer$264
- Lilly USA, LLC$209
- Otsuka America Pharmaceutical, Inc.$207
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,893100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 42 | $635 |
| Amgen | 27 | $516 |
| AstraZeneca | 24 | $390 |
| Pfizer | 14 | $264 |
| Lilly USA, LLC | 12 | $209 |
| Otsuka America Pharmaceutical, Inc. | 9 | $207 |
| Novo Nordisk | 8 | $154 |
| Sumitomo Pharma America, Inc. | 7 | $145 |
| Boehringer Ingelheim | 8 | $138 |
| Astellas Pharma US Inc | 6 | $135 |
| Bayer | 7 | $135 |
| Amarin Pharma, Inc. | 7 | $122 |
| E.r. Squibb & Sons, L.L.C. | 6 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
| Dexcom, Inc. | 4 | $79 |
| Abbott | 3 | $64 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| AbbVie | 3 | $56 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Johnson & Johnson | 4 | $50 |
| Cardiovascular Systems Inc. | 2 | $45 |
| Merck | 3 | $41 |
| Novartis | 2 | $35 |
| Smith+Nephew | 1 | $31 |
| Exact Sciences | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Renalytix AI, Inc. | 1 | $19 |
| RGH Enterprises LLC | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Lifescan, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
How this compares
$3,893 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 84 | $98,741 |
| EliquisApixaban | 92 | $89,964 |
| JanuviaSitagliptin Phosphate | 49 | $55,289 |
| ProliaDenosumab | 25 | $43,495 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $35,622 |
| OzempicSemaglutide | 14 | $25,082 |
| TradjentaLinagliptin | 13 | $20,034 |
| MyrbetriqMirabegron | 17 | $18,777 |
| VascepaIcosapent Ethyl | 25 | $17,049 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $16,686 |
| FarxigaDapagliflozin Propanediol | 20 | $16,576 |
| XareltoRivaroxaban | 11 | $16,256 |
| TrulicityDulaglutide | 17 | $15,501 |
| Spiriva RespimatTiotropium Bromide | 11 | $13,811 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $11,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $138 | $132,586108 claims |
| PfizerEliquis | $264 | $89,96492 claims |
| MerckJanuvia | $41 | $55,28949 claims |
| AmgenProlia | $516 | $43,49525 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $635 | $39,22056 claims |
| Novo NordiskOzempic | $154 | $25,08214 claims |
| AstraZenecaFarxiga, Symbicort | $390 | $22,73131 claims |
| Astellas Pharma US IncMyrbetriq | $135 | $18,77717 claims |
| Johnson & JohnsonXarelto | $50 | $16,25611 claims |
| Lilly USA, LLCTrulicity | $209 | $15,50117 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $145 | $10,49422 claims |
| AbbVieSynthroid | $56 | $3,01727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Garland
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.